Press Releases April 1, 2026 04:25 PM

Piedmont Realty Trust, Inc. to Report First Quarter 2026 Financial Results

Piedmont Realty Trust announces upcoming Q1 2026 earnings release and investor conference call

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
PDM

Piedmont Realty Trust, a NYSE-listed real estate investment company focused on Class A office properties in U.S. Sunbelt markets, will report its first quarter 2026 financial results on April 30, followed by a conference call on May 1 to discuss performance and recent developments.

Piedmont Realty Trust, Inc. to Report First Quarter 2026 Financial Results
PDM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The company manages approximately 16 million square feet of Class A office space in major U.S. Sunbelt markets.
  • Piedmont Realty Trust will release its Q1 2026 earnings on April 30, after market close, with a management conference call scheduled the following day.
  • The company emphasizes a hospitality-driven and client-focused approach in managing and developing office properties to enhance workplace experience.

Atlanta, GA, April 01, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust (NYSE: PDM) announced today that the Company will release its first quarter financial results on Thursday, April 30, 2026, after the close of trading on the New York Stock Exchange. A conference call is scheduled for Friday, May 1, 2026, at 9:00 a.m. ET and will be broadcast live in listen-only mode on the company’s investor relations website. During the conference call, the Company’s management team will review first quarter performance, discuss recent events, and conduct a question-and-answer period.

To Listen to the Live or Replay of the Webcast:
Click on the webcast link under the Investor Relations section of the Company's website at https://investor.piedmontreit.com/news-and-events/event-calendar

For analysts that are participating in the Conference Call:
Please dial in at least fifteen minutes prior to start time to ensure a timely connection.
Domestic: (888) 506-0062
International: (973) 528-0011
Participant Access Code: 820042

To Listen to the Replay Telephonically:
Domestic: (877) 481-4010
International: (919) 882-2331
Replay Passcode: 53839

The playback can be accessed through May 15, 2026.

About Piedmont Realty Trust

Piedmont Realty Trust™ (NYSE: PDM), is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of approximately 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into premier “Piedmont PLACEs” that enhance each client’s workplace experience.

Research Analysts/ Institutional Investors Contact:
770-418-8592
[email protected]

Shareholder Services/Transfer Agent Services Contact:
Computershare, Inc.
866-354-3485
[email protected]


Risks

  • The real estate sector remains sensitive to macroeconomic factors like interest rate fluctuations, which could impact future earnings.
  • The demand for office space could be affected by broader trends such as remote work, posing operational risks to office-focused REITs like Piedmont Realty Trust.
  • The company’s performance may be impacted by market conditions in the Sunbelt regional office property markets, which could fluctuate with local economic changes.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026